Humanitarian Grant Awarded for Preclinical Study on the Impact of NAD Precursor Vitamins on Milk Bioactive Production and Bra...
October 07 2019 - 6:30AM
Dr. Charles Brenner, the Roy J. Carver Chair and Head of
Biochemistry at the University of Iowa, receives a research
grant from the Bill & Melinda Gates Foundation to study the
effects of NAD-boosting supplements on the production of bioactive
factors in milk and the effect of the supplements on brain
development in animals.
Dr. Brenner explained that his previous research indicated that
a new mother’s body does everything in its power to provide for the
needs of her offspring: mobilizing her own protein, fat and
carbohydrate to make milk, mobilizing her own NAD precursors for
the offspring, and producing bioactive factors important for
the brain and physical development of her offspring. The new
mother’s body does so much that she experiences postpartum as a
metabolic stress.
“We addressed postpartum metabolic stress with nicotinamide
riboside (NR) – an important NAD precursor [or booster] - and
discovered that these supplemented mothers are more capable of
caring for their offspring, produce more nutritious milk, and spend
more time in nursing behavior, thereby giving their offspring
lasting neurodevelopmental advantages,” said Dr. Brenner. “With
this new project, we are keen to identify the degree to which NR is
uniquely capable of increasing expression of brain-derived
neurotrophic factor (BDNF), a naturally occurring compound critical
for brain development.”
Dr. Brenner’s work on postpartum as a metabolic stress piqued
the interest of the foundation, particularly as it may relate to
human mothers who live in conditions of sub-optimal nutrition and
other types of stress. At a convening on maternal health, the
foundation previewed Dr. Brenner’s work published earlier this year
in the journal Cell Reports, which showed that supplementation with
NR in animal models confers significant and enduring physiological
benefits to mothers and their offspring.
NR is also known as Niagen®, a form of vitamin B3 exclusively
licensed by ChromaDex (NASDAQ:CDXC). In 2004, Dr. Brenner
discovered the vitamin activity of NR through a gene pathway that
is activated when cells are under metabolic stress. He serves as
chief scientific advisor for ChromaDex.
“Through Dr. Brenner’s research on NR we can potentially improve
the wellbeing of mothers and their children in vulnerable
populations,” said ChromaDex CEO Rob Fried.
“This is an exciting opportunity to support the
humanitarian and scientific efforts of the foundation.”
For additional information on the science supporting Niagen
(nicotinamide riboside), please visit www.chromadex.com.
About ChromaDex:ChromaDex Corp. is a
science-based integrated nutraceutical company devoted to improving
the way people age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the
full potential of NAD and identify and develop novel, science-based
ingredients. Its flagship ingredient, NIAGEN® nicotinamide
riboside, sold directly to consumers as TRU NIAGEN®, is backed with
clinical and scientific research, as well as extensive IP
protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex
maintains a website at www.chromadex.com to which ChromaDex
regularly posts copies of its press releases as well as additional
and financial information about the Company.
Forward-Looking Statements:This release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities and Exchange Act of 1934, as amended. Statements
that are not a description of historical facts constitute
forward-looking statements and may often, but not always, be
identified by the use of such words as "expects", "anticipates",
"intends", "estimates", "plans", "potential", "possible",
"probable", "believes", "seeks", "may", "will", "should", "could"
or the negative of such terms or other similar expressions. More
detailed information about ChromaDex and the risk factors that may
affect the realization of forward-looking statements is set forth
in ChromaDex's Annual Report on Form 10-K for the fiscal year ended
December 31, 2018, ChromaDex's Quarterly Reports on Form 10-Q and
other filings submitted by ChromaDex to the SEC, copies of which
may be obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
ChromaDex Media Contact:Alex Worsham, Senior
Director of Global Corporate Communications310-388-6706 ext.
689alexw@chromadex.com
ChromaDex Investor Relations Contact:Brianna
Gerber, Senior Director of FP&A and Investor
Relations949-419-0288 ext. 127briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Sep 2023 to Sep 2024